

HR 7389

MVP Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 4, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 5, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7389>

Sponsor

Name: Rep. Schrader, Kurt [D-OR-5]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Apr 4, 2022
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Apr 4, 2022
Rep. Auchincloss, Jake [D-MA-4]	D · MA		Dec 13, 2022
Rep. Joyce, John [R-PA-13]	R · PA		Dec 13, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 5, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medicaid VBPs for Patients Act or the MVP Act

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (*Value-based purchasing arrangements* refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

Actions Timeline

- **Apr 5, 2022:** Referred to the Subcommittee on Health.
- **Apr 4, 2022:** Introduced in House
- **Apr 4, 2022:** Referred to the House Committee on Energy and Commerce.